ABVX financial statements
The full income statement, balance sheet, and cash-flow statement for Abivax SA American Depositary Shares (ABVX), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Research & development | 201M+26.9% | 159M+42.1% | 112M+119.6% | 50.8M-10.1% | 56.5M | |
| Operating income | -278M-48.8% | -187M-35.8% | -138M-102.0% | -68.2M-39.3% | -49.0M | |
| Interest expense | 126M+588.0% | 18.4M-39.0% | 30.1M+308.1% | 7.39M+75.4% | 4.21M | |
| Pre-tax income | -374M-96.0% | -191M-19.3% | -160M-150.0% | -63.9M-27.3% | -50.2M | |
| Income tax | 6.62M | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -380M-99.5% | -191M-19.3% | -160M-150.0% | -63.9M-27.3% | -50.2M | |
| -$5.47-80.4% | -$3.03+18.3% | -$3.71-10.9% | -$3.35-2.9% | -$3.25 | ||
| EPS (basic) | -$5.47-80.4% | -$3.03+18.3% | -$3.71-10.9% | -$3.35-2.9% | -$3.25 | |
| Weighted-avg shares (basic) | 69.5M+10.3% | 63.0M+46.4% | 43.1M+125.6% | 19.1M+23.5% | 15.5M | |
| Weighted-avg shares (diluted) | 69.5M+10.3% | 63.0M+46.4% | 43.1M+125.6% | 19.1M+23.5% | 15.5M | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 648M+265.3% | 177M-43.8% | 316M+715.5% | 38.7M-54.7% | 85.5M | ||
| Cash & equivalents | 607M+305.2% | 150M-46.1% | 278M+864.6% | 28.8M-58.1% | 68.7M | |
| 687M+222.1% | 213M-40.9% | 361M+346.7% | 80.8M-34.7% | 124M | ||
| Goodwill | 21.7M+13.1% | 19.1M-5.9% | 20.3M+3.2% | 19.7M-45.6% | 36.2M | |
| Total non-current assets | 38.9M+8.3% | 35.9M-20.8% | 45.4M+7.7% | 42.1M+10.2% | 38.2M | |
| Total current liabilities | 74.1M-24.2% | 97.7M-2.4% | 100M+81.8% | 55.1M+50.7% | 36.5M | |
| 535M+1168.7% | 42.2M-80.5% | 216M+2713.2% | 7.69M-73.8% | 29.4M | ||
| Total equity incl. non-controlling | 535M+1168.7% | 42.2M-80.5% | 216M+2713.2% | 7.69M-73.8% | 29.4M | |
| Common shares issued | 78.5M+24.0% | 63.3M+0.7% | 62.9M+182.0% | 22.3M+33.1% | 16.8M | |
| Common shares outstanding | — | 63.3M+0.7% | 62.9M+182.1% | 22.3M+33.1% | 16.8M | |
| Shares outstanding (cover) | 78.5M+24.0% | 63.3M+0.7% | 62.9M | — | — | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Cash from operations | -182M-9.4% | -167M-58.7% | -105M-85.1% | -56.7M-6.5% | -53.3M | |
| Capital expenditure | 161K-76.8% | 692K+141.6% | 287K-5.4% | 303K+445.0% | 55.6K | |
| Free cash flow | -182M-9.0% | -167M-58.9% | -105M-84.6% | -57.0M-7.0% | -53.3M | |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 733M | 0.00-100.0% | 382M+685.7% | 48.6M-41.0% | 82.4M | |
| Common stock repurchased | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 9.38B+1922.0% | 464M+94.3% | 239M | — | — | |
| P/B | 17.5×+59.4% | 11.0×-64.6% | 31.0× | — | — | |
| Source filing | 20-F | 20-F | 20-F | 10-K | 10-K |
About this data
Source: ABVX’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all ABVX filings on SEC EDGAR → Not investment advice.